One Shot. Five Years. Half of These Cancer Patients Are Still in Remission.
Half of relapsed multiple myeloma patients stayed cancer-free for five years after a single CAR-T infusion, with no maintenance therapy. Legend Biotech's latest CARVYKTI data is fueling talk of something oncologists rarely dare to whisper: a potential cure.
A Number That Changes Everything
In cancer, five years is a lifetime. Treatments come and go. Patients cycle through drug after drug, chasing remission like a moving target. So when a therapy delivers a single infusion and half the patients are still cancer-free five years later, that's not just good news. That's the kind of result that rewrites textbooks.
Legend Biotech just dropped long-term data on CARVYKTI, its CAR-T cell therapy for multiple myeloma. The headline: 50% of patients remained alive and progression-free after five years, following just one infusion. No maintenance pills. No follow-up treatments. One shot and done.
To appreciate why this matters, you need to understand what multiple myeloma usually looks like.
The Treadmill That Never Stops
Multiple myeloma is a blood cancer that forms in the bone marrow. It's the third most common blood cancer in the U.S., and for most patients, it follows a cruel pattern. You get treated. You go into remission. Then the cancer comes back, and you start again with a different drug. Rinse, repeat.
Doctors call each round a "line of therapy." Many patients go through four, five, even six lines over their lifetime. Each successive treatment tends to work a little less well and a little less long. It's like patching a tire that keeps springing new leaks; eventually, you run out of patches.
That's why the idea of a one-time treatment that could put a significant chunk of patients into long-term remission sounds almost too good to be true.
What CARVYKTI Actually Does
CAR-T therapy (short for chimeric antigen receptor T-cell therapy) works like a biological software update for your immune system. Doctors take a patient's own T-cells, the soldiers of the immune system, and genetically reprogram them in a lab to recognize and attack cancer cells. Then they infuse those supercharged cells back into the patient.
CARVYKTI specifically targets a protein called BCMA that sits on the surface of myeloma cells. Think of it like giving your immune cells a mugshot of the cancer, so they know exactly who to hunt down.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The treatment is already approved and generating serious revenue. Full-year 2025 sales hit $1.9 billion, and the product grew over 50% year-over-year in Q2 2026. Legend Biotech and its partner Johnson & Johnson have been scaling manufacturing aggressively, pushing their success rate to 99% and delivering more than 95% of orders on time.
But sales numbers don't tell you whether a cancer therapy actually works over the long haul. For that, you need years of follow-up. And that's exactly what Legend just delivered.
The Data, Decoded
The five-year results come from a study called CARTITUDE-2 Cohort A, a Phase 2 trial of 20 patients with relapsed or refractory multiple myeloma. These patients had already been through one to three prior lines of therapy and weren't responding to a key drug called lenalidomide.
After a median follow-up of 60.7 months (just over five years), here's what the data showed:
Ten out of twenty patients were still alive and progression-free. No cancer growing. No new treatments needed. The median progression-free survival clocked in at 60.5 months, meaning half the patients went more than five years before their disease progressed, if it progressed at all.
The overall survival rate at five years was 69.2%, and the median overall survival hadn't even been reached yet. In clinical-trial speak, "not reached" is actually a good thing; it means more than half the patients are still alive and the statisticians can't calculate a midpoint yet.
Perhaps the most striking detail: among the three patients who underwent deep molecular testing at five years, all three were MRD-negative at a sensitivity of one in a million. MRD stands for minimal residual disease, and being negative at that depth means scientists couldn't find a single cancer cell among a million bone marrow cells. That's about as close to "cured" as oncology gets without actually using the word.
Small Study, Big Implications
Let's address the elephant in the room. Twenty patients is a small study. In biotech, small studies can produce flashy numbers that don't hold up in larger populations. A single patient relapsing or staying in remission can swing the percentage by five points. So healthy skepticism is warranted.
But this data doesn't exist in a vacuum. Legend also has five-year results from CARTITUDE-1, an earlier study of 97 patients who were more heavily pretreated (meaning they'd already been through more rounds of therapy). In that tougher population, 33% remained progression-free at five years. That's less dramatic than the 50% figure, but it comes from a bigger dataset and a sicker group of patients.
The pattern tells a consistent story: CARVYKTI's benefits are durable, and they appear to get even better when the therapy is used earlier in a patient's treatment journey, before the cancer has had multiple chances to evolve resistance.
The Competitive Landscape: Not Even Close?
CARVYKTI isn't the only CAR-T therapy for myeloma. Bristol Myers Squibb's Abecma (idecabtagene vicleucel) was actually the first BCMA-directed CAR-T to reach the market. But when it comes to long-term durability, the gap is striking.
Abecma's pivotal KarMMa-3 trial showed a median progression-free survival of about 13.3 months. Compare that to CARVYKTI's 60.5 months. That's not a marginal difference; it's a substantial gap. Now, cross-trial comparisons are always imperfect because the patient populations, study designs, and treatment histories differ. But even with those caveats, CARVYKTI's durability signal stands in a league of its own among approved myeloma CAR-T therapies.
Then there are bispecific antibodies, a newer class of off-the-shelf drugs that also target BCMA. Products like teclistamab are moving into earlier treatment lines and don't require the weeks-long manufacturing process that CAR-T demands. They're more convenient, but so far, they haven't shown the kind of long, treatment-free remissions that CARVYKTI is producing.
The emerging expert consensus in 2026 is clear: if a patient is eligible for both CAR-T and bispecifics, use CAR-T first. The reasoning is practical. Bispecifics still seem to work after CAR-T, but CAR-T may work less well after bispecific exposure. It's like using your best closer in the ninth inning, not burning him in the sixth and hoping the bullpen holds.
The "C" Word
Oncologists are famously careful about the word "cure." Cancer can hide. It can return after a decade. Declaring victory too early has burned the field before.
But Legend Biotech is starting to lean into the idea of "curative potential," at least for a subset of patients. And the data supports the language, carefully. When patients are five years out from a single infusion with no detectable disease at one-in-a-million sensitivity, the conversation naturally shifts from "how long will this last?" to "is this over?"
The safety profile at five years also matters. Since an earlier data cut, one patient developed acute myeloid leukemia (a known, rare risk with CAR-T therapy), and two deaths occurred. No new cases of CAR-T-related neurotoxicity showed up in the extended follow-up. These risks are real but relatively contained, especially weighed against the alternative of cycling through treatment after treatment indefinitely.
What This Means for the Future of Myeloma
The standard playbook for newly diagnosed myeloma in 2026 still starts with combination chemotherapy regimens (often including drugs like daratumumab, bortezomib, and lenalidomide), plus stem cell transplant for eligible patients. CAR-T isn't a frontline option yet.
But the trajectory is unmistakable. Data like this pushes CAR-T earlier and earlier in the treatment sequence. If one infusion can deliver five-plus years of treatment-free remission for a meaningful fraction of patients, the calculus around waiting through multiple relapses before pulling the trigger starts to look outdated.
Multiple clinical trials are now testing both CAR-T and bispecific antibodies in earlier settings, including second-line and even frontline combinations. The field is racing toward a future where the most powerful weapons are deployed sooner rather than saved as last resorts.
The Bottom Line
Twenty patients is not a definitive answer. But 50% alive and progression-free at five years, after a single infusion, with no maintenance therapy is the kind of signal that makes the entire myeloma community sit up.
For Legend Biotech, the data validates a commercial juggernaut already approaching $3 billion in annualized revenue. For patients, it offers something that's been painfully rare in multiple myeloma: genuine hope that the treadmill might actually stop.
And for the broader field of cell therapy? This is the proof of concept that everyone has been waiting for. Not just that CAR-T works, but that it can keep working, quietly, for years after a single treatment. If that's not worth paying attention to, nothing in biotech is.
Science & Discovery5 min read
One Shot to Kill Your Cholesterol. Forever.
A single IV dose silenced the cholesterol gene PCSK9 for nearly a year in monkeys, slashing LDL by up to 70%. If it works in humans, it could replace daily statins with a one-and-done treatment.
